Weight loss in obese individuals may lead to reduced pain, affect, and somatic symptoms associated with chronic pain.
There is no statistically significant difference in weight loss at 5 years after laparoscopic sleeve gastrectomy vs laparoscopic Roux-en-Y gastric bypass in morbidly obese patients.
More than 40 diet plans across 9 categories have been ranked to help those dieting achieve healthier lifestyles in U.S News & World Report.
The AspireAssist device has been approved for treatment of obese patients with a BMI of 35 to 55.
New guidelines support use of metabolic surgery as standard treatment option for type 2 diabetes, obesityJune 01, 2016
A panel of experts has recommended that metabolic surgery be included as a treatment option for patients with type 2 diabetes and obesity.
Patients who were obese and underwent bariatric surgery saw a significant reduction in heart failure-related exacerbation events.
People who lose greater amounts of weight per decade later in life have an increased risk of mild cognitive impairment.
HHS and USDA have released the latest edition of dietary guidelines for Americans that focus on healthy eating patterns and preventing chronic diseases.
Gastric bypass surgery improves patient well-being, though symptom prevalence, hospitalization rate high afterwardJanuary 06, 2016
About 90% of patients who undergo gastric bypass surgery experience 1 or more related symptoms afterward.
After steadily gaining weight for 10 years, an obese patient seeks help in achieving sustained, long-term weight loss.
Compared with other dietary interventions, low-fat diets are not more effective for long-term weight loss.
Changes in alcohol metabolism, substituting substances for food, and hormone changes may increase the risk for suicide after bariatric surgery.
A patient visits her primary care physician for a two-year follow-up after a Roux-en-Y gastric bypass surgery to check for complications.
Saxenda is adjunct to reduced-calorie diet and increased physical activity for chronic weight management.
Obese patients who rated their clinicians as very helpful lost more weight than those who gave them low ratings.
Encouraging patients to get more sleep each night may help them lose weight.
Older adults with dementia who took cholinesterase inhibitors had an increased risk of weight loss.
With lifestyle counseling, 3mg of liraglutide helped 63% of participants lose at least 5% body weight.
Nearly 20% of patients lost more than 5% of their baseline weight by 52 weeks or less when assigned to receive apremilast.
Those who had a choice lost slightly less weight compared with patients who had no choice.
In general, adult patients gained more weight as the glycemic load in their diets rose.
Weight losses were similar in all groups, but insulin sensitivity index values increased two-fold more in the calorie reduction and exercise group.
Women who thought smoking does help control weight did not significantly increase their attempts to quit in response to a price increase.
From all 10 lifestyle intervention groups, the pooled within-group effect on weight (3,063 patients) was −5.33 kg.
Compared with the weight-gain group, the incidence of diabetes was significantly lower in the highest quartile weight-loss group.
Eisai has launched a new savings card for lorcaserin (Belviq) to increase the affordability and accessibility of the weight-loss drug.
Smaller and more gradual changes in diet and physical activity can help patients lose weight and improve health.
The Maestro Rechargeable System has been approved by the FDA to treat obese patients with at least one obesity-related condition.
The FDA has approved Saxenda (liraglutide [rDNA origin]) injection for chronic weight management.
The rate of diabetes decreased for up to seven years after bariatric surgery for obese patients.